Mantle cell lymphoma is a relatively rare type of #cancer that starts in immune cells called B-cells. Often, this disease is diagnosed in patients 60 years or older and occurs more often in men.
Mantle cell lymphoma (MCL) can be aggressive, particularly if found in its more advanced stages, or can act as a slow-growing cancer in its earlier stages.
Treatment for MCL varies considerably, depending upon how far the cancer has spread, its aggressiveness, previous therapy that has been received, and the overall health, age, and other medical issues of the patient.
Rituxan is an agent that is commonly used in the treatment of MCL, and targets specific proteins that are expressed on the surface of B cell, called CD 20. Revlimid was approved in 2013 for the treatment of MCL that has already been treated with at least 2 prior therapies, but recurred.
The treatment combination consisting of Revlimid® (lenalidomide) plus Rituxan® (rituximab) provides high rates of long-lasting anti-cancer responses when used as initial therapy for mantle cell lymphoma. These results were recently published in the New England Journal of Medicine.
I have first hand experience with this rare form of cancer and this medicine and can say it works for me 3+ years in remission and going strong …